Home › NDC Lookup › RxCUI directory › RxCUI 1299917

Tiagabine hydrochloride 4 MG Oral Tablet — RxCUI 1299917

RxNorm drug concept · Semantic clinical drug
RxCUI 1299917 Semantic clinical drug · SCD ● Current RxNorm concept 10 FDA products 14 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1299917
Official nameTiagabine hydrochloride 4 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astiaGABine HCl 4 MG Oral Tablet
FDA products mapped10
Package NDCs mapped14
Reported Medicaid activity (SDUD)2,499 prescriptions · 23 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tiagabine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tiagabine is used to help control partial seizures in adults and teens 12 and older. It's not a stand-alone medicine — it's always added to at least one other seizure medication yo...
  • Yes, every single dose should be taken with food. That's how tiagabine was studied in all the clinical trials. Food slows down how quickly it's absorbed, which helps keep things st...
  • Do I have to take it with food every time?
  • The most common ones are dizziness, tiredness, drowsiness, nausea, shakiness (tremor), and trouble concentrating — most are mild to moderate and often happen early in treatment as...
📖 Read our full Tiagabine guide →

🕸️ Concept Web — How Tiagabine hydrochloride 4 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tiagabine hydrochloride 4 MG Oral Tablet RxCUI 1299917

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Tiagabine 31914
    • Tiagabine hydrochloride 236875
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gabitril 217243
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tiagabine Oral Tablet 374123
    • Tiagabine hydrochloride Oral Tablet 2648604
    • Tiagabine Oral Product 1162089
    • Tiagabine Pill 1162090
    • Tiagabine hydrochloride Oral Product 2663642
    • Tiagabine hydrochloride Pill 2659651
    • Tiagabine Oral Tablet [Gabitril] 368199
    • Tiagabine hydrochloride Oral Tablet [Gabitril] 2657490
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Tiagabine hydrochloride 4 MG 1299915
    • Tiagabine hydrochloride 4 MG Oral Tablet [Gabitril] 1299978
    • Tiagabine hydrochloride 4 MG [Gabitril] 1299977

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tiagabine hydrochloride 4 MG SCDC · 1299915
  • Tiagabine Oral Tablet SCDF · 374123
  • Tiagabine hydrochloride Oral Tablet SCDFP · 2648604
  • Tiagabine Oral Product SCDG · 1162089
  • Tiagabine Pill SCDG · 1162090
  • Tiagabine hydrochloride Oral Product SCDGP · 2663642
  • Tiagabine hydrochloride Pill SCDGP · 2659651

Brand-Name Concepts

  • Tiagabine hydrochloride 4 MG Oral Tablet [Gabitril] SBD · 1299978
  • Tiagabine hydrochloride 4 MG [Gabitril] SBDC · 1299977
  • Tiagabine Oral Tablet [Gabitril] SBDF · 368199
  • Tiagabine hydrochloride Oral Tablet [Gabitril] SBDFP · 2657490
  • Gabitril Oral Product SBDG · 1175365
  • Gabitril Pill SBDG · 1175366
  • Gabitril BN · 217243

📦 FDA Products & Package NDCs

10 products · 14 package NDCs
14 package NDCs map to RxCUI 1299917 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00093-5030-56 30 TABLET, FILM COATED in 1 BOTTLE (0093-5030-56) Tiagabine Hydrochloride Teva Pharmaceuticals USA, Inc. 2016-06-03
00093-5031-56 30 TABLET, FILM COATED in 1 BOTTLE (0093-5031-56) Tiagabine Hydrochloride Teva Pharmaceuticals USA, Inc. 2016-07-18
00093-8072-56 30 TABLET, FILM COATED in 1 BOTTLE (0093-8072-56) Tiagabine Hydrochloride Teva Pharmaceuticals USA, Inc. 2018-03-09
00093-8076-56 30 TABLET, FILM COATED in 1 BOTTLE (0093-8076-56) Tiagabine Hydrochloride Teva Pharmaceuticals USA, Inc. 2018-03-09
62756-0200-18 1000 TABLET, FILM COATED in 1 BOTTLE (62756-200-18) TIAGABINE HYDROCHLORIDE Sun Pharmaceutical Industries, Inc. 2011-11-04
62756-0200-83 30 TABLET, FILM COATED in 1 BOTTLE (62756-200-83) TIAGABINE HYDROCHLORIDE Sun Pharmaceutical Industries, Inc. 2011-11-04
62756-0224-08 100 TABLET, FILM COATED in 1 BOTTLE (62756-224-08) TIAGABINE HYDROCHLORIDE Sun Pharmaceutical Industries, Inc. 2011-11-04
62756-0224-18 1000 TABLET, FILM COATED in 1 BOTTLE (62756-224-18) TIAGABINE HYDROCHLORIDE Sun Pharmaceutical Industries, Inc. 2011-11-04
62756-0224-83 30 TABLET, FILM COATED in 1 BOTTLE (62756-224-83) TIAGABINE HYDROCHLORIDE Sun Pharmaceutical Industries, Inc. 2011-11-04
62756-0224-88 100 TABLET, FILM COATED in 1 BOTTLE (62756-224-88) TIAGABINE HYDROCHLORIDE Sun Pharmaceutical Industries, Inc. 2011-11-04
72205-0084-30 30 TABLET in 1 BOTTLE (72205-084-30) Tiagabine Hydrochloride Novadoz Pharmaceuticals LLC 2021-11-23
72205-0085-30 30 TABLET in 1 BOTTLE (72205-085-30) Tiagabine Hydrochloride Novadoz Pharmaceuticals LLC 2021-11-23
72205-0086-30 30 TABLET in 1 BOTTLE (72205-086-30) Tiagabine Hydrochloride Novadoz Pharmaceuticals LLC 2021-11-23
72205-0087-30 30 TABLET in 1 BOTTLE (72205-087-30) Tiagabine Hydrochloride Novadoz Pharmaceuticals LLC 2021-11-23
Observed labelers: Sun Pharmaceutical Industries, Inc. (6) · Novadoz Pharmaceuticals LLC (4) · Teva Pharmaceuticals USA, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.